Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072380 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
A Phase 2 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT04072380 is a Phase 2 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 190 participants.
The verdict
NCT04072380, a Phase 2 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
This study is of an investigational drug called SUVN-G3031 (Samelisant) as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy. The main purpose of this study is to learn how well the study drug works and how safe the study drug is compared to placebo.
Interventions
- DRUG Placebo
- DRUG SUVN-G3031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2019-09-21 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04072380
The ClinicalTrials.gov registry entry for NCT04072380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04072380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04072380 about?
NCT04072380 is a clinical study titled "A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy". This study is of an investigational drug called SUVN-G3031 (Samelisant) as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy. The main purpose of this study is to learn how well the study drug works and how safe the study drug is compared to placebo.
What is the current status of trial NCT04072380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2019-09-21. Estimated completion is 2023-06-13.
What interventions are being tested in trial NCT04072380?
The interventions under investigation include: Placebo (DRUG), SUVN-G3031 (DRUG).
Who is sponsoring clinical trial NCT04072380?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.